

Appendix 3. Summary of findings table

Certainty assessment							No of patients		Effect		Certainty	Importance
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Transdermal GTN	Control/placebo therapy	Relative (95% CIs)	Absolute (95% CIs)		
In-hospital mortality (follow up: range 1 day to 3 months) [Primary Outcome]												
Mean arterial pressure (follow up: range 1 day to 10 days) [Primary Outcome]												
Modified Rankin Scale (follow up: range 3 months to 12 months) [Primary Outcome]												
Development of intracerebral haemorrhage (follow up: range 1 day to 10 days) [Secondary Outcome]												
Deterioration of NIHSS scores by at least 4 points during hospitalization (follow up: range 1 day to 10 days) [Secondary Outcome]												
Length of hospital stay (follow up: range 1 day to 3 months) [Secondary Outcome]												
Number of hypotensive episodes requiring intervention* (follow up: range 1 day to 10 days) [Safety Outcome]												

GTN: Glyceryl trinitrate; CIs: Confidence intervals; NIHSS: National Institutes of Health Stroke Scale

*Interventions include discontinuing transdermal GTN, administration of intravenous fluids and/or inotropic drugs